Breaking the cycle of recurrent vaginal yeast infections.

Recurrent vaginal infection is an undervalued market ripe for disruption.

Over 6 million women in the U.S. suffer three or more yeast infections each year, and nearly 20 million battle persistent bacterial vaginosis. These conditions can cause relentless discomfort—itching, burning, and discharge—while impacting self-esteem and intimacy.

Standard of care relies on constant use of antifungals or antibiotics, which disrupt microbiome function, cause liver and kidney disease, and are often contraindicated in pregnancy (when yeast infections are especially common).

With the high demand for a sustained, patient-friendly solution, we have an immense opportunity to transform care in this under-served market.

Anti-infectives are tools to reset, but not to resolve.

Following a course of anti-infectives, the pathogen often returns. Moreover, the void left by anti-infective use may lead to colonization by other undesirable microbes. More anti-infectives won’t break the cycle.

The real solution lies in the microbiome: By restoring a healthy microbial community that naturally wards off pathogens, we can re-establish a long-lasting defense against infection.

ENS-003 will reliably inhibit C. albicans virulence.

Many healthy women carry C. albicans in their vaginal microbiome without issue—until disruption from antibiotics or other factors throws the ecosystem off balance. When this happens, C. albicans shifts from harmless to harmful, producing invasive hyphae and toxins that trigger inflammation, itching, and burning.

A microbial intervention could stop this transition at its source. By reinforcing mechanisms of the natural protective microbiome, ENS-003 is designed to prevent C. albicans from turning virulent, offering a lasting solution for recurrent vaginal yeast infections.